Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts

Gynecologic Oncology

Volumn 102, Issue 3, 2006, Pages 462-467

  Masters, Gregg R ^a   Berger, Marc A ^a   Albone, Earl F ^a  

^a PURDUE PHARMA L P   (United States)

Author keywords

90Y; CA 125; DOTA; Ovarian cancer; Paclitaxel; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MONOCLONAL ANTIBODY 776.1 Y 90; CA 125 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MPOC 21; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; ISOTOPE LABELING; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; CARCINOMA; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 33748602368     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.004     Document Type: Article

References (44)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer statistics, 2001. C. A. Cancer J. Clin. 51 (2001) 15
2. Vasey P.A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br. J. Cancer 89 Suppl 3 (2003) S23
3. Ozols R.F., Schwartz P.E., and Eifel P.J. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principals and practice of oncology. sixth ed. vol. 2 (2001), Lippincott, Williams, and Wilkins, Philadelphia 1597
4. Leake J., Woolas R.P., Daniel J., et al. Immunocytochemical and serological expression of CA 125: a clinicopathological study of 40 malignant ovarian epithelial tumours. Histopathology 24 (1994) 57
5. Loy T.S., Quesenberry J.T., and Sharp S.C. Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am. J. Clin. Pathol. 98 (1992) 175
6. Ginath S., Menczer J., Fintsi Y., et al. Tissue and serum CA125 expression in endometrial cancer. Int. J. Gynecol. Cancer 12 (2002) 372
7. Gadducci A., Cosio S., Carpi A., et al. Serum tumor markers in the management of ovarian, endometrial, and cervical cancer. Biomed. Pharmacother. 58 (2004) 24
8. Batlle M., Ribera J.M., Oriol A., et al. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. Leuk. Lymphoma 46 (2005) 1471
9. Buccheri G., and Ferrigno D. Lung tumor markers in oncology practice: a study of TPA and CA 125. Br. J. Cancer 87 (2002) 1112
10. Norum L.F., Erikstein B., and Nustad K. Elevated CA 125 in breast cancer-a sign of advanced disease. Tumor Biol. 22 (2001) 223
11. Meden H., and Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int. J. Biol. Markers 13 (1998) 231
12. Vaidya A.P., and Curtin J.P. The follow-up of ovarian cancer. Semin. Oncol. 30 (2003) 401
13. Tuxen M.K., Soletormos G., and Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br. J. Cancer 84 (2001) 1301
14. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 (1996) 1545
15. Haisma H.J., Battaile A., Stradtman E.W., et al. Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer. Int. J. Cancer 40 (1987) 758
16. Singleton J, Guillen DE, Scully MS, et al. Characterization of antibodies to CA 125 that bind preferentially to the cell-associated form of the antigen. Tumor Biol [in press].
17. Berger MA, Masters G, Singleton J, et al. Pharmacokinetics, biodistribution, and radioimmunotherapy with 776.1 in a murine model of human ovarian cancer. Cancer Biotherapy Radiopharm [in press]
18. McGuire W.P., and Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer 89 Suppl 3 (2003) S3
19. Harries M., and Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3 (2002) 529
20. De Brabaner M., Geuens G., Nuydens R., et al. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc. Nat. Acad. Sci. 78 (1981) 5608
21. Blagosklonny M.V., Schulte T., Nguyen P., et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56 (1996) 1851
22. Oyaizu H., Adachi Y., Taketani S., et al. A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis. Mol. Cell Biol. Res. Commun. 2 (1999) 36
23. Moos P.J., and Fitzpatrick F.A. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ. 9 (1998) 687
24. Denardo S.J., Richman C.M., Kukis D.L., et al. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Res. 18 (1998) 4011
25. DeNardo S.J., Kukis D.L., Kroger L.A., et al. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Nat. Acad. Sci. 94 (1997) 4000
26. Liebmann J., Cook J.A., Fisher J., et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. 86 (1994) 441
27. Hamilton T.C., Young R.C., McKoy W.M., et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43 (1983) 5379
28. Burbridge M.F., Kraus-Berthier L., Naze M., et al. Biological and pharmacological characterization of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumor activity. Int. J. Oncol. 15 (1999) 1155
29. Guichard S., Montazeri A., Chatelut E., et al. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokineitic and pharmacodynamic evaluation. Clin. Cancer Res. 7 (2001) 3222
30. Lewis M.R., Kao J.Y., Anderson A.L., Shively J.E., and Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjugate Chem. 12 (2001) 320
31. Lewis M.R., Raubitschek A., and Shively J.E. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. 5 (1994) 565
32. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248
33. Dadachova E., Chappell L.L., and Brechbiel M.W. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl. Med. Biol. 26 (1999) 977
34. Polin L., Valeriote F., White K., et al. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest. New Drugs 15 (1997) 99
35. Bissery M.C., Guenard D., Gueritte-Voegelein F., and Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51 (1991) 4845
36. Yokoyama Y., Dhanabal M., Griffioen A.W., et al. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 60 (2000) 2190
37. Prewett M.C., Hooper A.T., Bassi R., et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8 (2002) 994
38. Alvarez R.D., Huh W.K., Khazaeli M.B., Meredith R.F., et al. A Phase I study of combined modality (90)yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8 (2002) 2806
39. Nicholson S., Gooden C.S., Hird V., et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol. Rep. 5 (1998) 223
40. Kievit E., Pinedo H.M., Schluper H.M., et al. Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int. J. Radiat. Oncol. Biol. Phys. 38 (1997) 419
41. Kolfschoten G.M., Hulscher T.M., Duyndam M.C., et al. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem. Pharmacol. 63 (2002) 733
42. Chadebech P., Brichese L., Baldin V., et al. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem. Biophys. Res. Commun. 262 (1999) 823
43. Steren A., Sevin B.U., Perras J., et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol. Oncol. 48 (1993) 252
44. Blumenthal R.D., Leone E., and Goldenberg D.M. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res. 23 (2003) 4613